CYP4B1 inhibits lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a CYP4B1-related prognostic signature
CYP4B1 functions as a tumor suppressor in LUAD, regulated by NFIA and exerting its effects through PI3K/AKT/mTOR pathway inhibition. The CRRS and nomogram provide potential tools for prognosis assessment and offer guidance for precision therapy in LUAD, pending further translational validation.
Authors
- G. Z. Li
- Xiaoyan Li (ORCID: https://orcid.org/0000-0003-1910-2464)
- Jing Kang (ORCID: https://orcid.org/0009-0009-2874-3678)
- Liping Zhao (ORCID: https://orcid.org/0000-0003-2756-2030)
- Chenlu Gong
- Zhiqiang Liu
- Bi Zhang
Institutions
- Zhoukou Normal University (CN)
- Shanxi Academy of Medical Sciences (CN)
- Shanxi Provincial People’s Hospital (CN)
- Shaanxi Normal University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fonc.2025.1661650
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00